China Risun Group（1907）株式概要中国理順集団有限公司は、その子会社とともに、中華人民共和国において、コークス、原料用化学品、精製化学品の生産、販売、流通を行っている。 詳細1907 ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長3/6過去の実績3/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より79.9%で取引されている 収益は年間51.45%増加すると予測されています 過去1年間で収益は188.1%増加しました 同業他社や業界と比較して、良好な取引価格 リスク分析利払いは収益で十分にカバーされない 財務結果に影響を与える大きな一時的項目 Hong Kong市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る1907 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueHK$Current PriceHK$2.6622.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-507m58b2016201920222025202620282031Revenue CN¥57.9bEarnings CN¥85.5mAdvancedSet Fair ValueView all narrativesChina Risun Group Limited 競合他社Sinopec Shanghai PetrochemicalSymbol: SEHK:338Market cap: HK$27.7bLee & Man ChemicalSymbol: SEHK:746Market cap: HK$3.9bChina Sanjiang Fine ChemicalsSymbol: SEHK:2198Market cap: HK$5.4bYip's Chemical HoldingsSymbol: SEHK:408Market cap: HK$1.3b価格と性能株価の高値、安値、推移の概要China Risun Group過去の株価現在の株価HK$2.6652週高値HK$4.2452週安値HK$2.15ベータ0.391ヶ月の変化-16.09%3ヶ月変化6.40%1年変化7.26%3年間の変化-22.90%5年間の変化-55.22%IPOからの変化-6.67%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Xiaofeng Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 30China Risun Group Limited, Annual General Meeting, May 29, 2026China Risun Group Limited, Annual General Meeting, May 29, 2026.お知らせ • Mar 17China Risun Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026China Risun Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Aug 19China Risun Group Limited to Report First Half, 2025 Results on Aug 29, 2025China Risun Group Limited announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • May 30China Risun Group Limited Approves and Declares Special Dividend, Expected Payable on June 30, 2025China Risun Group Limited at its AGM held on May 30, 2025 approved and declared a special dividend of RMB 2.22 cents per share (the "Special Dividend") to be paid in Hong Kong dollars of an amount of HK 2.40 cents per share (tax-inclusive) out of the share premium account of the Company. As the resolution for the payment of the Special Dividend was duly passed at the AGM, the Company will pay the Special Dividend in cash for the year ended December 31, 2024 to the Shareholders whose names appear on the register of members of the Company on June 13, 2025 (the "Record Date"), and the payment date is expected to be June 30, 2025. Ex-dividend date is 9 June 2025.お知らせ • Mar 29China Risun Group Limited, Annual General Meeting, May 30, 2025China Risun Group Limited, Annual General Meeting, May 30, 2025.最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Xiaofeng Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 30China Risun Group Limited, Annual General Meeting, May 29, 2026China Risun Group Limited, Annual General Meeting, May 29, 2026.お知らせ • Mar 17China Risun Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026China Risun Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026お知らせ • Aug 19China Risun Group Limited to Report First Half, 2025 Results on Aug 29, 2025China Risun Group Limited announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • May 30China Risun Group Limited Approves and Declares Special Dividend, Expected Payable on June 30, 2025China Risun Group Limited at its AGM held on May 30, 2025 approved and declared a special dividend of RMB 2.22 cents per share (the "Special Dividend") to be paid in Hong Kong dollars of an amount of HK 2.40 cents per share (tax-inclusive) out of the share premium account of the Company. As the resolution for the payment of the Special Dividend was duly passed at the AGM, the Company will pay the Special Dividend in cash for the year ended December 31, 2024 to the Shareholders whose names appear on the register of members of the Company on June 13, 2025 (the "Record Date"), and the payment date is expected to be June 30, 2025. Ex-dividend date is 9 June 2025.お知らせ • Mar 29China Risun Group Limited, Annual General Meeting, May 30, 2025China Risun Group Limited, Annual General Meeting, May 30, 2025.お知らせ • Mar 18China Risun Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025China Risun Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025お知らせ • Dec 27China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million.China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million. Security Name: Shares Security Type: Common Stock Securities Offered: 52,000,000 Price\Range: HKD 3 Transaction Features: Subsequent Direct Listingお知らせ • Oct 10China Risun Group Limited Announces Liu Xiaofeng as Independent Non-Executive Director and A Member of the Audit CommitteeThe Board of China Risun Group Limited announced that Dr Liu Xiaofeng has been appointed as an INED and a member of the Audit Committee, effective from October 10, 2024. Dr. Liu Xiaofeng, aged 62, obtained a master ' s degree and a Ph.D. in development economics from University of Cambridge in October 1988 and May 1994 respectively. He also obtained a master's degree in Development Studies from the University of Bath in December 1987, and a bachelor's degree in economics from Southwest University of Finance and Economics in China (previously known as Sichuan Institute of Finance and Economics) in July 1983. Dr. Liu has approximately 32 years of experience in corporate finance and has worked in various international financial institutions since 1993, including N M Rothschild & Sons Limited, N M Rothschild & Sons (Hong Kong) Limited, JPMorgan Chase, DBS Asia Capital Limited, China Resources Capital Holdings Company Limited and UBS Securities Co., Limited. He also served as an independent non-executive director at Haier Electronics Group Co. Ltd. (stock code: 1169) from June 2007 to June 2014, at Hisense Home Appliances Group Co. Ltd. (stock code: 921) from September 2017 to August 2018, at Honghua Group Limited (stock code: 196) from January 2008 to November 2021, at AAG Energy Holdings Limited (stock code: 2686, delisted in July 2023) from August 2018 to August 2023, and at Cinda International Holdings Limited (stock code: 111) from July 2016 to July 2024. Currently, he has been an independent non-executive director at KunLun Energy Company Limited (stock code: 135) since April 2004, at Sunfonda Group Holdings Limited (stock code: 1771) since May 2017, at Logory Logistics Technology Co. Ltd. (stock code: 2482) since March 2023. Moreover, Dr. Liu has been the vice president of the China Independent Non-executive Directors Association since August 2023.Reported Earnings • Sep 29First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023)First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 30First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023)First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Aug 28China Risun Group Limited Announces Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2024, Payable on 30 September 2024China Risun Group Limited announced ordinary interim (semi-annual) dividend of RMB 0.0078 per share for the six months ended June 30, 2024. Ex-dividend date: 09 September 2024. Record date: 13 September 2024. Payment date: 30 September 2024.お知らせ • Aug 14China Risun Group Limited to Report First Half, 2024 Results on Aug 23, 2024China Risun Group Limited announced that they will report first half, 2024 results on Aug 23, 2024Recent Insider Transactions • Jul 23CEO & Chairman recently bought HK$1.5m worth of stockOn the 16th of July, Xuegang Yang bought around 500k shares on-market at roughly HK$2.99 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$48m worth in shares.お知らせ • Jul 15China Risun Group Limited Announces Board and Committee ChangesChina Risun Group Limited announced that Mr. Kang Woon (Mr. Kang) resigned as an independent non-executive director of the company (INED), the chairman of the remuneration committee and a member of each of the nomination committee and audit committee under the board on July 15, 2024 as he received a bankruptcy order dated June 25, 2024 issued by the High Court of Hong Kong against him. Mr. Kang further informed the company that he is considering taking all necessary actions to discharge his bankruptcy order, including, but not limited to, exploring legal options in Hong Kong, such as filing an appeal with the High Court of Hong Kong. Change of composition of board committees: To fill the vacancies of a member of the nomination committee and the chairman of the remuneration committee under the Board, the Board resolved to appoint Mr. Wang Yinping as a member of the nomination committee; and appoint Mr. Wang Yinping, an existing committee member, as the chairman of the remuneration committee and Mr. Li Qinghua as a member of the remuneration committee.Recent Insider Transactions • Jul 10CEO & Chairman recently bought HK$1.1m worth of stockOn the 4th of July, Xuegang Yang bought around 368k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$46m worth in shares.Recent Insider Transactions • Jun 26CEO & Chairman recently bought HK$13m worth of stockOn the 21st of June, Xuegang Yang bought around 4m shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$44m worth in shares.Recent Insider Transactions • Jun 15CEO & Chairman recently bought HK$1.1m worth of stockOn the 11th of June, Xuegang Yang bought around 358k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.3m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$29m worth in shares.Recent Insider Transactions • Jun 11CEO & Chairman recently bought HK$1.3m worth of stockOn the 3rd of June, Xuegang Yang bought around 424k shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$28m worth in shares.お知らせ • May 31China Risun Group Limited Approves Final Ordinary Dividend for the Fiscal Year Ended 31 December 2023, Payable on 28 June 2024China Risun Group Limited at its AGM held on 30 May 2024 approved Final Ordinary dividend for the fiscal year ended 31 December 2023. Dividend declared is RMB 0.012 per share. Ex-dividend date is 07 June 2024. Record date is 14 June 2024. Payment date is 28 June 2024.Upcoming Dividend • May 31Upcoming dividend of HK$0.013 per shareEligible shareholders must have bought the stock before 07 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 2.2%. Lower than top quartile of Hong Kong dividend payers (7.6%). Lower than average of industry peers (4.7%).Buy Or Sell Opportunity • May 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.6% to HK$3.24. The fair value is estimated to be HK$2.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 33%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 341% in the next 2 years.Reported Earnings • Apr 30Full year 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.20 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Declared Dividend • Apr 29Final dividend increased to HK$0.013Dividend of HK$0.013 is 32% higher than last year. Ex-date: 7th June 2024 Payment date: 28th June 2024 Dividend yield will be 2.2%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 140% over the next 2 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 28China Risun Group Limited, Annual General Meeting, May 30, 2024China Risun Group Limited, Annual General Meeting, May 30, 2024, at 10:00 China Standard Time. Location: Room 2001, 20/F., Sino Plaza, 255 Gloucester Road, Causeway Bay, Hong Kong Causeway Bay Hong Kong Agenda: To consider and approve the report of the board of directors of the Company for the year ended December 31, 2023; to consider and approve the audited financial statements of the Company and the independent auditor's report for the year ended December 31, 2023; to re-elect Ms. Lu Xiaomei as an executive director of the Company; to re-elect Mr. Li Qinghua as an executive director of the Company; to re-elect Mr. Wang Nianping as an executive director of the Company; to authorize the board of directors of the Company to fix the remuneration of the directors of the Company for the year ending December 31, 2024; and to consider other business matters.お知らせ • Apr 26China Risun Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 28 June 2024China Risun Group Limited proposed final dividend of RMB 0.012 per share for the year ended December 31, 2023. Date of shareholders' approval is 30 May 2024, Ex-dividend date is 07 June 2024, Record date is 14 June 2024 and Payment date is 28 June 2024.Reported Earnings • Mar 16Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.19 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • Mar 15China Risun Group Limited Announces Final Cash Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024China Risun Group Limited announced final cash dividend of RMB 0.012 per share for the year ended 31 December 2023. Payment date is 28 June 2024.お知らせ • Mar 02China Risun Group Limited to Report Fiscal Year 2023 Results on Mar 14, 2024China Risun Group Limited announced that they will report fiscal year 2023 results on Mar 14, 2024Recent Insider Transactions • Dec 03CEO & Chairman recently bought HK$3.9m worth of stockOn the 30th of November, Xuegang Yang bought around 1m shares on-market at roughly HK$3.18 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$143m worth in shares.Recent Insider Transactions • Nov 10CEO & Chairman recently bought HK$3.1m worth of stockOn the 7th of November, Xuegang Yang bought around 968k shares on-market at roughly HK$3.19 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$135m worth in shares.Recent Insider Transactions • Oct 23CEO & Chairman recently bought HK$1.6m worth of stockOn the 17th of October, Xuegang Yang bought around 502k shares on-market at roughly HK$3.17 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$136m worth in shares.Recent Insider Transactions • Sep 16CEO & Chairman recently bought HK$1.3m worth of stockOn the 15th of September, Xuegang Yang bought around 400k shares on-market at roughly HK$3.24 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$122m worth in shares.Upcoming Dividend • Sep 04Upcoming dividend of HK$0.053 per share at 4.0% yieldEligible shareholders must have bought the stock before 11 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 4.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (7.7%).New Risk • Aug 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 123% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.0% net profit margin).お知らせ • Aug 26China Risun Group Limited Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2023, Payable on 29 September 2023China Risun Group Limited declared ordinary interim (semi-annual) dividend of RMB 0.049 per share for the six months ended June 30, 2023. Ex-dividend date: 8 September 2023. Record date: 15 September 2023. Payment date: 29 September 2023.お知らせ • Aug 16China Risun Group Limited to Report First Half, 2023 Results on Aug 25, 2023China Risun Group Limited announced that they will report first half, 2023 results on Aug 25, 2023Upcoming Dividend • Jun 05Upcoming dividend of HK$0.01 per share at 4.3% yieldEligible shareholders must have bought the stock before 12 June 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 4.3%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (7.5%).お知らせ • May 31China Risun Group Limited Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable on or Before June 30, 2023China Risun Group Limited announced final ordinary of RMB 0.009 dividend for the year ended December 31, 2022, payable on 30 June 2023, Record date is 16 June 2023 and Ex dividend: 12 June 2023.Recent Insider Transactions • May 09CEO & Chairman recently bought HK$11m worth of stockOn the 3rd of May, Xuegang Yang bought around 3m shares on-market at roughly HK$3.54 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$98m worth in shares.Recent Insider Transactions • Apr 28CEO & Chairman recently bought HK$11m worth of stockOn the 24th of April, Xuegang Yang bought around 3m shares on-market at roughly HK$3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$66m worth in shares.Recent Insider Transactions • Apr 13CEO & Chairman recently bought HK$6.7m worth of stockOn the 6th of April, Xuegang Yang bought around 2m shares on-market at roughly HK$3.34 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$13m worth in shares.Reported Earnings • Apr 01Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (down from CN¥0.61 in FY 2021). Revenue: CN¥43.1b (up 12% from FY 2021). Net income: CN¥1.86b (down 29% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 17% per year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Recent Insider Transactions • Nov 05CEO & Chairman recently bought HK$3.0m worth of stockOn the 28th of October, Xuegang Yang bought around 1m shares on-market at roughly HK$2.89 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$6.1m worth in shares.Buying Opportunity • Sep 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be HK$4.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%.Buying Opportunity • Aug 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be HK$3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%.Reported Earnings • Aug 28First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.41 in 1H 2021)First half 2022 results: EPS: CN¥0.39. Revenue: CN¥22.5b (up 25% from 1H 2021). Net income: CN¥1.74b (up 2.7% from 1H 2021). Profit margin: 7.7% (down from 9.4% in 1H 2021). The decrease in margin was driven by higher expenses.Recent Insider Transactions • Jul 07Board Member recently bought HK$1.3m worth of stockOn the 4th of July, Lu Yang bought around 400k shares on-market at roughly HK$3.21 per share. In the last 3 months, they made an even bigger purchase worth HK$3.1m. Insiders have collectively bought HK$56m more in shares than they have sold in the last 12 months.Upcoming Dividend • Jun 07Upcoming dividend of HK$0.077 per shareEligible shareholders must have bought the stock before 14 June 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 5.8%. Lower than top quartile of Hong Kong dividend payers (7.7%). In line with average of industry peers (5.3%).Reported Earnings • May 02Full year 2021 earnings released: EPS: CN¥0.61 (vs CN¥0.40 in FY 2020)Full year 2021 results: EPS: CN¥0.61 (up from CN¥0.40 in FY 2020). Revenue: CN¥38.4b (up 94% from FY 2020). Net income: CN¥2.61b (up 58% from FY 2020). Profit margin: 6.8% (down from 8.4% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 21%, compared to a 9.0% growth forecast for the industry in Hong Kong.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Recent Insider Transactions • Apr 12Board Member recently bought HK$815k worth of stockOn the 7th of April, Lu Yang bought around 200k shares on-market at roughly HK$4.07 per share. In the last 3 months, they made an even bigger purchase worth HK$3.6m. Insiders have collectively bought HK$58m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Apr 03Board Member recently bought HK$399k worth of stockOn the 29th of March, Lu Yang bought around 100k shares on-market at roughly HK$3.99 per share. In the last 3 months, they made an even bigger purchase worth HK$3.6m. Insiders have collectively bought HK$57m more in shares than they have sold in the last 12 months.Reported Earnings • Mar 29Full year 2021 earnings released: EPS: CN¥0.61 (vs CN¥0.42 in FY 2020)Full year 2021 results: EPS: CN¥0.61 (up from CN¥0.42 in FY 2020). Revenue: CN¥38.4b (up 94% from FY 2020). Net income: CN¥2.61b (up 54% from FY 2020). Profit margin: 6.8% (down from 8.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.3%, compared to a 10% growth forecast for the industry in Hong Kong.Board Change • Mar 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Recent Insider Transactions • Jan 08Board Member recently bought HK$685k worth of stockOn the 6th of January, Lu Yang bought around 150k shares on-market at roughly HK$4.57 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$49m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Dec 18Board Member recently bought HK$1.6m worth of stockOn the 15th of December, Lu Yang bought around 350k shares on-market at roughly HK$4.52 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$44m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 10Board Member recently bought HK$771k worth of stockOn the 5th of November, Lu Yang bought around 170k shares on-market at roughly HK$4.53 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$41m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Oct 30CEO & Chairman recently bought HK$9.4m worth of stockOn the 27th of October, Xuegang Yang bought around 2m shares on-market at roughly HK$4.70 per share. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$30m worth in shares.Recent Insider Transactions • Oct 22Board Member recently bought HK$974k worth of stockOn the 18th of October, Lu Yang bought around 203k shares on-market at roughly HK$4.80 per share. In the last 3 months, they made an even bigger purchase worth HK$1.2m. Insiders have collectively bought HK$25m more in shares than they have sold in the last 12 months.Reported Earnings • Oct 03First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.086 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥18.0b (up 121% from 1H 2020). Net income: CN¥1.69b (up 382% from 1H 2020). Profit margin: 9.4% (up from 4.3% in 1H 2020). The increase in margin was driven by higher revenue.Recent Insider Transactions • Sep 30Board Member recently bought HK$1.2m worth of stockOn the 24th of September, Lu Yang bought around 250k shares on-market at roughly HK$5.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.5m. Insiders have collectively bought HK$24m more in shares than they have sold in the last 12 months.Reported Earnings • Aug 30First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.086 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥18.0b (up 121% from 1H 2020). Net income: CN¥1.69b (up 382% from 1H 2020). Profit margin: 9.4% (up from 4.3% in 1H 2020). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥5.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 165% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$3.62 per share.Recent Insider Transactions • Jul 22Board Member recently bought HK$533k worth of stockOn the 16th of July, Lu Yang bought around 110k shares on-market at roughly HK$4.84 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.5m. Insiders have collectively bought HK$16m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jul 13CEO & Chairman recently bought HK$9.5m worth of stockOn the 8th of July, Xuegang Yang bought around 2m shares on-market at roughly HK$4.75 per share. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares.Recent Insider Transactions • Jul 03CEO & Chairman recently bought HK$6.2m worth of stockOn the 29th of June, Xuegang Yang bought around 1m shares on-market at roughly HK$4.99 per share. This was the largest purchase by an insider in the last 3 months. This was Xuegang's only on-market trade for the last 12 months.Upcoming Dividend • Jun 03Upcoming dividend of HK$0.12 per shareEligible shareholders must have bought the stock before 10 June 2021. Payment date: 30 June 2021. Trailing yield: 2.5%. Lower than top quartile of Hong Kong dividend payers (5.9%). Lower than average of industry peers (3.5%).Valuation Update With 7 Day Price Move • May 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥6.03, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 166% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$3.55 per share.Reported Earnings • Apr 25Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥19.8b (up 5.0% from FY 2019). Net income: CN¥1.70b (up 25% from FY 2019). Profit margin: 8.6% (up from 7.2% in FY 2019). The increase in margin was driven by higher revenue.Reported Earnings • Mar 28Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥19.8b (up 5.0% from FY 2019). Net income: CN¥1.70b (up 25% from FY 2019). Profit margin: 8.6% (up from 7.2% in FY 2019). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥4.22, the stock is trading at a trailing P/E ratio of 16.6x, down from the previous P/E ratio of 20.2x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 76%.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥5.11, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 17.2x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 103%.Is New 90 Day High Low • Feb 17New 90-day high: HK$5.12The company is up 108% from its price of HK$2.46 on 19 November 2020. The Hong Kong market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 33% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.14 per share.Is New 90 Day High Low • Jan 25New 90-day high: HK$4.50The company is up 106% from its price of HK$2.18 on 28 October 2020. The Hong Kong market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 45% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.13 per share.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 31% share price gain to CN¥3.61, the stock is trading at a trailing P/E ratio of 14.1x, up from the previous P/E ratio of 10.8x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 47%.Is New 90 Day High Low • Jan 08New 90-day high: HK$3.61The company is up 63% from its price of HK$2.21 on 09 October 2020. The Hong Kong market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.13 per share.Is New 90 Day High Low • Dec 22New 90-day high: HK$2.70The company is up 25% from its price of HK$2.16 on 24 September 2020. The Hong Kong market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$1.89 per share.Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 17% share price gain to CN¥2.60, the stock is trading at a trailing P/E ratio of 10.4x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 7x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 3.7%.Is New 90 Day High Low • Nov 06New 90-day high: HK$2.54The company is up 20% from its price of HK$2.11 on 07 August 2020. The Hong Kong market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$1.53 per share.Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of CN¥872.4m, down 61% from the prior year. Total revenue was CN¥16.9b over the last 12 months, down 18% from the prior year.株主還元1907HK ChemicalsHK 市場7D-4.3%-2.5%-1.5%1Y7.3%27.1%11.3%株主還元を見る業界別リターン: 1907過去 1 年間で27.1 % の収益を上げたHong Kong Chemicals業界を下回りました。リターン対市場: 1907は、過去 1 年間で11.3 % のリターンを上げたHong Kong市場を下回りました。価格変動Is 1907's price volatile compared to industry and market?1907 volatility1907 Average Weekly Movement10.8%Chemicals Industry Average Movement7.2%Market Average Movement7.3%10% most volatile stocks in HK Market15.7%10% least volatile stocks in HK Market3.5%安定した株価: 1907の株価は、 Hong Kong市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1907の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてHong Kongの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19957,131Xuegang Yangwww.risun.com中国理順集団有限公司は、その子会社とともに、中華人民共和国において、コークス、原料化学品、精製化学品の生産、販売、流通を行っている。4つのセグメントで事業を展開している：コークス・原料用化学品製造、精製化学品製造、操業管理、貿易の4つのセグメントで事業を展開している。同社のコークス用化学品および精製化学品には、粗ベンゼン、工業用ナフタレン無水フタル酸、コークス炉ガスメタノール、コールタール、高純度水素、カプロラクタムなどがある。また、第三者であるコークスメーカーや精製化学メーカーに対する操業管理サービスや、安全管理や操業技術に関するトレーニングサービスも提供している。さらに、コークス、原料化学品、精製化学品の取引、不動産開発活動も行っている。同社は鉄鋼、非鉄、コークス、化学産業の企業にサービスを提供している。製品の輸出も行っている。中国理順集団有限公司は1995年に設立され、中華人民共和国の北京に本社を置く。もっと見るChina Risun Group Limited 基礎のまとめChina Risun Group の収益と売上を時価総額と比較するとどうか。1907 基礎統計学時価総額HK$11.37b収益（TTM）HK$66.90m売上高(TTM)HK$45.31b170.0xPER（株価収益率0.3xP/Sレシオ1907 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1907 損益計算書（TTM）収益CN¥39.29b売上原価CN¥36.22b売上総利益CN¥3.06bその他の費用CN¥3.01b収益CN¥58.01m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.014グロス・マージン7.80%純利益率0.15%有利子負債／自己資本比率228.2%1907 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.2%現在の配当利回り29%配当性向1907 配当は確実ですか？1907 配当履歴とベンチマークを見る1907 、いつまでに購入すれば配当金を受け取れますか？China Risun Group 配当日配当落ち日Jun 08 2026配当支払日Jun 30 2026配当落ちまでの日数15 days配当支払日までの日数37 days1907 配当は確実ですか？1907 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 02:26終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋China Risun Group Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Jie HuangCitic Securities Co., Ltd.Margaret LiPhillip Securities (HK)Kun ZhaiTopsperity Securities2 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Xiaofeng Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 30China Risun Group Limited, Annual General Meeting, May 29, 2026China Risun Group Limited, Annual General Meeting, May 29, 2026.
お知らせ • Mar 17China Risun Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026China Risun Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Aug 19China Risun Group Limited to Report First Half, 2025 Results on Aug 29, 2025China Risun Group Limited announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • May 30China Risun Group Limited Approves and Declares Special Dividend, Expected Payable on June 30, 2025China Risun Group Limited at its AGM held on May 30, 2025 approved and declared a special dividend of RMB 2.22 cents per share (the "Special Dividend") to be paid in Hong Kong dollars of an amount of HK 2.40 cents per share (tax-inclusive) out of the share premium account of the Company. As the resolution for the payment of the Special Dividend was duly passed at the AGM, the Company will pay the Special Dividend in cash for the year ended December 31, 2024 to the Shareholders whose names appear on the register of members of the Company on June 13, 2025 (the "Record Date"), and the payment date is expected to be June 30, 2025. Ex-dividend date is 9 June 2025.
お知らせ • Mar 29China Risun Group Limited, Annual General Meeting, May 30, 2025China Risun Group Limited, Annual General Meeting, May 30, 2025.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Xiaofeng Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 30China Risun Group Limited, Annual General Meeting, May 29, 2026China Risun Group Limited, Annual General Meeting, May 29, 2026.
お知らせ • Mar 17China Risun Group Limited to Report Fiscal Year 2025 Results on Mar 27, 2026China Risun Group Limited announced that they will report fiscal year 2025 results on Mar 27, 2026
お知らせ • Aug 19China Risun Group Limited to Report First Half, 2025 Results on Aug 29, 2025China Risun Group Limited announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • May 30China Risun Group Limited Approves and Declares Special Dividend, Expected Payable on June 30, 2025China Risun Group Limited at its AGM held on May 30, 2025 approved and declared a special dividend of RMB 2.22 cents per share (the "Special Dividend") to be paid in Hong Kong dollars of an amount of HK 2.40 cents per share (tax-inclusive) out of the share premium account of the Company. As the resolution for the payment of the Special Dividend was duly passed at the AGM, the Company will pay the Special Dividend in cash for the year ended December 31, 2024 to the Shareholders whose names appear on the register of members of the Company on June 13, 2025 (the "Record Date"), and the payment date is expected to be June 30, 2025. Ex-dividend date is 9 June 2025.
お知らせ • Mar 29China Risun Group Limited, Annual General Meeting, May 30, 2025China Risun Group Limited, Annual General Meeting, May 30, 2025.
お知らせ • Mar 18China Risun Group Limited to Report Fiscal Year 2024 Results on Mar 28, 2025China Risun Group Limited announced that they will report fiscal year 2024 results on Mar 28, 2025
お知らせ • Dec 27China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million.China Risun Group Limited has completed a Follow-on Equity Offering in the amount of HKD 156 million. Security Name: Shares Security Type: Common Stock Securities Offered: 52,000,000 Price\Range: HKD 3 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 10China Risun Group Limited Announces Liu Xiaofeng as Independent Non-Executive Director and A Member of the Audit CommitteeThe Board of China Risun Group Limited announced that Dr Liu Xiaofeng has been appointed as an INED and a member of the Audit Committee, effective from October 10, 2024. Dr. Liu Xiaofeng, aged 62, obtained a master ' s degree and a Ph.D. in development economics from University of Cambridge in October 1988 and May 1994 respectively. He also obtained a master's degree in Development Studies from the University of Bath in December 1987, and a bachelor's degree in economics from Southwest University of Finance and Economics in China (previously known as Sichuan Institute of Finance and Economics) in July 1983. Dr. Liu has approximately 32 years of experience in corporate finance and has worked in various international financial institutions since 1993, including N M Rothschild & Sons Limited, N M Rothschild & Sons (Hong Kong) Limited, JPMorgan Chase, DBS Asia Capital Limited, China Resources Capital Holdings Company Limited and UBS Securities Co., Limited. He also served as an independent non-executive director at Haier Electronics Group Co. Ltd. (stock code: 1169) from June 2007 to June 2014, at Hisense Home Appliances Group Co. Ltd. (stock code: 921) from September 2017 to August 2018, at Honghua Group Limited (stock code: 196) from January 2008 to November 2021, at AAG Energy Holdings Limited (stock code: 2686, delisted in July 2023) from August 2018 to August 2023, and at Cinda International Holdings Limited (stock code: 111) from July 2016 to July 2024. Currently, he has been an independent non-executive director at KunLun Energy Company Limited (stock code: 135) since April 2004, at Sunfonda Group Holdings Limited (stock code: 1771) since May 2017, at Logory Logistics Technology Co. Ltd. (stock code: 2482) since March 2023. Moreover, Dr. Liu has been the vice president of the China Independent Non-executive Directors Association since August 2023.
Reported Earnings • Sep 29First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023)First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 30First half 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.16 in 1H 2023)First half 2024 results: EPS: CN¥0.025 (down from CN¥0.16 in 1H 2023). Revenue: CN¥25.2b (up 21% from 1H 2023). Net income: CN¥111.9m (down 84% from 1H 2023). Profit margin: 0.4% (down from 3.4% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 28China Risun Group Limited Announces Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2024, Payable on 30 September 2024China Risun Group Limited announced ordinary interim (semi-annual) dividend of RMB 0.0078 per share for the six months ended June 30, 2024. Ex-dividend date: 09 September 2024. Record date: 13 September 2024. Payment date: 30 September 2024.
お知らせ • Aug 14China Risun Group Limited to Report First Half, 2024 Results on Aug 23, 2024China Risun Group Limited announced that they will report first half, 2024 results on Aug 23, 2024
Recent Insider Transactions • Jul 23CEO & Chairman recently bought HK$1.5m worth of stockOn the 16th of July, Xuegang Yang bought around 500k shares on-market at roughly HK$2.99 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$48m worth in shares.
お知らせ • Jul 15China Risun Group Limited Announces Board and Committee ChangesChina Risun Group Limited announced that Mr. Kang Woon (Mr. Kang) resigned as an independent non-executive director of the company (INED), the chairman of the remuneration committee and a member of each of the nomination committee and audit committee under the board on July 15, 2024 as he received a bankruptcy order dated June 25, 2024 issued by the High Court of Hong Kong against him. Mr. Kang further informed the company that he is considering taking all necessary actions to discharge his bankruptcy order, including, but not limited to, exploring legal options in Hong Kong, such as filing an appeal with the High Court of Hong Kong. Change of composition of board committees: To fill the vacancies of a member of the nomination committee and the chairman of the remuneration committee under the Board, the Board resolved to appoint Mr. Wang Yinping as a member of the nomination committee; and appoint Mr. Wang Yinping, an existing committee member, as the chairman of the remuneration committee and Mr. Li Qinghua as a member of the remuneration committee.
Recent Insider Transactions • Jul 10CEO & Chairman recently bought HK$1.1m worth of stockOn the 4th of July, Xuegang Yang bought around 368k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$13m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$46m worth in shares.
Recent Insider Transactions • Jun 26CEO & Chairman recently bought HK$13m worth of stockOn the 21st of June, Xuegang Yang bought around 4m shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$44m worth in shares.
Recent Insider Transactions • Jun 15CEO & Chairman recently bought HK$1.1m worth of stockOn the 11th of June, Xuegang Yang bought around 358k shares on-market at roughly HK$3.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$1.3m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$29m worth in shares.
Recent Insider Transactions • Jun 11CEO & Chairman recently bought HK$1.3m worth of stockOn the 3rd of June, Xuegang Yang bought around 424k shares on-market at roughly HK$3.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$28m worth in shares.
お知らせ • May 31China Risun Group Limited Approves Final Ordinary Dividend for the Fiscal Year Ended 31 December 2023, Payable on 28 June 2024China Risun Group Limited at its AGM held on 30 May 2024 approved Final Ordinary dividend for the fiscal year ended 31 December 2023. Dividend declared is RMB 0.012 per share. Ex-dividend date is 07 June 2024. Record date is 14 June 2024. Payment date is 28 June 2024.
Upcoming Dividend • May 31Upcoming dividend of HK$0.013 per shareEligible shareholders must have bought the stock before 07 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 2.2%. Lower than top quartile of Hong Kong dividend payers (7.6%). Lower than average of industry peers (4.7%).
Buy Or Sell Opportunity • May 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.6% to HK$3.24. The fair value is estimated to be HK$2.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 33%. Revenue is forecast to grow by 42% in 2 years. Earnings are forecast to grow by 341% in the next 2 years.
Reported Earnings • Apr 30Full year 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.20 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Declared Dividend • Apr 29Final dividend increased to HK$0.013Dividend of HK$0.013 is 32% higher than last year. Ex-date: 7th June 2024 Payment date: 28th June 2024 Dividend yield will be 2.2%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 140% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 28China Risun Group Limited, Annual General Meeting, May 30, 2024China Risun Group Limited, Annual General Meeting, May 30, 2024, at 10:00 China Standard Time. Location: Room 2001, 20/F., Sino Plaza, 255 Gloucester Road, Causeway Bay, Hong Kong Causeway Bay Hong Kong Agenda: To consider and approve the report of the board of directors of the Company for the year ended December 31, 2023; to consider and approve the audited financial statements of the Company and the independent auditor's report for the year ended December 31, 2023; to re-elect Ms. Lu Xiaomei as an executive director of the Company; to re-elect Mr. Li Qinghua as an executive director of the Company; to re-elect Mr. Wang Nianping as an executive director of the Company; to authorize the board of directors of the Company to fix the remuneration of the directors of the Company for the year ending December 31, 2024; and to consider other business matters.
お知らせ • Apr 26China Risun Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 28 June 2024China Risun Group Limited proposed final dividend of RMB 0.012 per share for the year ended December 31, 2023. Date of shareholders' approval is 30 May 2024, Ex-dividend date is 07 June 2024, Record date is 14 June 2024 and Payment date is 28 June 2024.
Reported Earnings • Mar 16Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.42 in FY 2022)Full year 2023 results: EPS: CN¥0.19 (down from CN¥0.42 in FY 2022). Revenue: CN¥46.1b (up 6.8% from FY 2022). Net income: CN¥860.8m (down 54% from FY 2022). Profit margin: 1.9% (down from 4.3% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 15China Risun Group Limited Announces Final Cash Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024China Risun Group Limited announced final cash dividend of RMB 0.012 per share for the year ended 31 December 2023. Payment date is 28 June 2024.
お知らせ • Mar 02China Risun Group Limited to Report Fiscal Year 2023 Results on Mar 14, 2024China Risun Group Limited announced that they will report fiscal year 2023 results on Mar 14, 2024
Recent Insider Transactions • Dec 03CEO & Chairman recently bought HK$3.9m worth of stockOn the 30th of November, Xuegang Yang bought around 1m shares on-market at roughly HK$3.18 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$143m worth in shares.
Recent Insider Transactions • Nov 10CEO & Chairman recently bought HK$3.1m worth of stockOn the 7th of November, Xuegang Yang bought around 968k shares on-market at roughly HK$3.19 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$135m worth in shares.
Recent Insider Transactions • Oct 23CEO & Chairman recently bought HK$1.6m worth of stockOn the 17th of October, Xuegang Yang bought around 502k shares on-market at roughly HK$3.17 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$3.8m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$136m worth in shares.
Recent Insider Transactions • Sep 16CEO & Chairman recently bought HK$1.3m worth of stockOn the 15th of September, Xuegang Yang bought around 400k shares on-market at roughly HK$3.24 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$122m worth in shares.
Upcoming Dividend • Sep 04Upcoming dividend of HK$0.053 per share at 4.0% yieldEligible shareholders must have bought the stock before 11 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 4.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (7.7%).
New Risk • Aug 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 123% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.0x net interest cover). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.0% net profit margin).
お知らせ • Aug 26China Risun Group Limited Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended June 30, 2023, Payable on 29 September 2023China Risun Group Limited declared ordinary interim (semi-annual) dividend of RMB 0.049 per share for the six months ended June 30, 2023. Ex-dividend date: 8 September 2023. Record date: 15 September 2023. Payment date: 29 September 2023.
お知らせ • Aug 16China Risun Group Limited to Report First Half, 2023 Results on Aug 25, 2023China Risun Group Limited announced that they will report first half, 2023 results on Aug 25, 2023
Upcoming Dividend • Jun 05Upcoming dividend of HK$0.01 per share at 4.3% yieldEligible shareholders must have bought the stock before 12 June 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 4.3%. Lower than top quartile of Hong Kong dividend payers (7.8%). Lower than average of industry peers (7.5%).
お知らせ • May 31China Risun Group Limited Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable on or Before June 30, 2023China Risun Group Limited announced final ordinary of RMB 0.009 dividend for the year ended December 31, 2022, payable on 30 June 2023, Record date is 16 June 2023 and Ex dividend: 12 June 2023.
Recent Insider Transactions • May 09CEO & Chairman recently bought HK$11m worth of stockOn the 3rd of May, Xuegang Yang bought around 3m shares on-market at roughly HK$3.54 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$98m worth in shares.
Recent Insider Transactions • Apr 28CEO & Chairman recently bought HK$11m worth of stockOn the 24th of April, Xuegang Yang bought around 3m shares on-market at roughly HK$3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$11m. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$66m worth in shares.
Recent Insider Transactions • Apr 13CEO & Chairman recently bought HK$6.7m worth of stockOn the 6th of April, Xuegang Yang bought around 2m shares on-market at roughly HK$3.34 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$13m worth in shares.
Reported Earnings • Apr 01Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.42 (down from CN¥0.61 in FY 2021). Revenue: CN¥43.1b (up 12% from FY 2021). Net income: CN¥1.86b (down 29% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 17% per year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Recent Insider Transactions • Nov 05CEO & Chairman recently bought HK$3.0m worth of stockOn the 28th of October, Xuegang Yang bought around 1m shares on-market at roughly HK$2.89 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$6.1m worth in shares.
Buying Opportunity • Sep 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be HK$4.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%.
Buying Opportunity • Aug 31Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be HK$3.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 18%.
Reported Earnings • Aug 28First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.41 in 1H 2021)First half 2022 results: EPS: CN¥0.39. Revenue: CN¥22.5b (up 25% from 1H 2021). Net income: CN¥1.74b (up 2.7% from 1H 2021). Profit margin: 7.7% (down from 9.4% in 1H 2021). The decrease in margin was driven by higher expenses.
Recent Insider Transactions • Jul 07Board Member recently bought HK$1.3m worth of stockOn the 4th of July, Lu Yang bought around 400k shares on-market at roughly HK$3.21 per share. In the last 3 months, they made an even bigger purchase worth HK$3.1m. Insiders have collectively bought HK$56m more in shares than they have sold in the last 12 months.
Upcoming Dividend • Jun 07Upcoming dividend of HK$0.077 per shareEligible shareholders must have bought the stock before 14 June 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 5.8%. Lower than top quartile of Hong Kong dividend payers (7.7%). In line with average of industry peers (5.3%).
Reported Earnings • May 02Full year 2021 earnings released: EPS: CN¥0.61 (vs CN¥0.40 in FY 2020)Full year 2021 results: EPS: CN¥0.61 (up from CN¥0.40 in FY 2020). Revenue: CN¥38.4b (up 94% from FY 2020). Net income: CN¥2.61b (up 58% from FY 2020). Profit margin: 6.8% (down from 8.4% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 21%, compared to a 9.0% growth forecast for the industry in Hong Kong.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Recent Insider Transactions • Apr 12Board Member recently bought HK$815k worth of stockOn the 7th of April, Lu Yang bought around 200k shares on-market at roughly HK$4.07 per share. In the last 3 months, they made an even bigger purchase worth HK$3.6m. Insiders have collectively bought HK$58m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Apr 03Board Member recently bought HK$399k worth of stockOn the 29th of March, Lu Yang bought around 100k shares on-market at roughly HK$3.99 per share. In the last 3 months, they made an even bigger purchase worth HK$3.6m. Insiders have collectively bought HK$57m more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 29Full year 2021 earnings released: EPS: CN¥0.61 (vs CN¥0.42 in FY 2020)Full year 2021 results: EPS: CN¥0.61 (up from CN¥0.42 in FY 2020). Revenue: CN¥38.4b (up 94% from FY 2020). Net income: CN¥2.61b (up 54% from FY 2020). Profit margin: 6.8% (down from 8.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.3%, compared to a 10% growth forecast for the industry in Hong Kong.
Board Change • Mar 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Non-Executive Director Yinping Wang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Recent Insider Transactions • Jan 08Board Member recently bought HK$685k worth of stockOn the 6th of January, Lu Yang bought around 150k shares on-market at roughly HK$4.57 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$49m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Dec 18Board Member recently bought HK$1.6m worth of stockOn the 15th of December, Lu Yang bought around 350k shares on-market at roughly HK$4.52 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$44m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 10Board Member recently bought HK$771k worth of stockOn the 5th of November, Lu Yang bought around 170k shares on-market at roughly HK$4.53 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.4m. Insiders have collectively bought HK$41m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Oct 30CEO & Chairman recently bought HK$9.4m worth of stockOn the 27th of October, Xuegang Yang bought around 2m shares on-market at roughly HK$4.70 per share. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$30m worth in shares.
Recent Insider Transactions • Oct 22Board Member recently bought HK$974k worth of stockOn the 18th of October, Lu Yang bought around 203k shares on-market at roughly HK$4.80 per share. In the last 3 months, they made an even bigger purchase worth HK$1.2m. Insiders have collectively bought HK$25m more in shares than they have sold in the last 12 months.
Reported Earnings • Oct 03First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.086 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥18.0b (up 121% from 1H 2020). Net income: CN¥1.69b (up 382% from 1H 2020). Profit margin: 9.4% (up from 4.3% in 1H 2020). The increase in margin was driven by higher revenue.
Recent Insider Transactions • Sep 30Board Member recently bought HK$1.2m worth of stockOn the 24th of September, Lu Yang bought around 250k shares on-market at roughly HK$5.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.5m. Insiders have collectively bought HK$24m more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 30First half 2021 earnings released: EPS CN¥0.41 (vs CN¥0.086 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥18.0b (up 121% from 1H 2020). Net income: CN¥1.69b (up 382% from 1H 2020). Profit margin: 9.4% (up from 4.3% in 1H 2020). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥5.60, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 165% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$3.62 per share.
Recent Insider Transactions • Jul 22Board Member recently bought HK$533k worth of stockOn the 16th of July, Lu Yang bought around 110k shares on-market at roughly HK$4.84 per share. In the last 3 months, there was an even bigger purchase from another insider worth HK$9.5m. Insiders have collectively bought HK$16m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jul 13CEO & Chairman recently bought HK$9.5m worth of stockOn the 8th of July, Xuegang Yang bought around 2m shares on-market at roughly HK$4.75 per share. This was the largest purchase by an insider in the last 3 months. Xuegang has been a buyer over the last 12 months, purchasing a net total of HK$16m worth in shares.
Recent Insider Transactions • Jul 03CEO & Chairman recently bought HK$6.2m worth of stockOn the 29th of June, Xuegang Yang bought around 1m shares on-market at roughly HK$4.99 per share. This was the largest purchase by an insider in the last 3 months. This was Xuegang's only on-market trade for the last 12 months.
Upcoming Dividend • Jun 03Upcoming dividend of HK$0.12 per shareEligible shareholders must have bought the stock before 10 June 2021. Payment date: 30 June 2021. Trailing yield: 2.5%. Lower than top quartile of Hong Kong dividend payers (5.9%). Lower than average of industry peers (3.5%).
Valuation Update With 7 Day Price Move • May 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥6.03, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 166% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$3.55 per share.
Reported Earnings • Apr 25Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥19.8b (up 5.0% from FY 2019). Net income: CN¥1.70b (up 25% from FY 2019). Profit margin: 8.6% (up from 7.2% in FY 2019). The increase in margin was driven by higher revenue.
Reported Earnings • Mar 28Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.34 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥19.8b (up 5.0% from FY 2019). Net income: CN¥1.70b (up 25% from FY 2019). Profit margin: 8.6% (up from 7.2% in FY 2019). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥4.22, the stock is trading at a trailing P/E ratio of 16.6x, down from the previous P/E ratio of 20.2x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 76%.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥5.11, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 17.2x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 103%.
Is New 90 Day High Low • Feb 17New 90-day high: HK$5.12The company is up 108% from its price of HK$2.46 on 19 November 2020. The Hong Kong market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 33% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.14 per share.
Is New 90 Day High Low • Jan 25New 90-day high: HK$4.50The company is up 106% from its price of HK$2.18 on 28 October 2020. The Hong Kong market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 45% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.13 per share.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 31% share price gain to CN¥3.61, the stock is trading at a trailing P/E ratio of 14.1x, up from the previous P/E ratio of 10.8x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 47%.
Is New 90 Day High Low • Jan 08New 90-day high: HK$3.61The company is up 63% from its price of HK$2.21 on 09 October 2020. The Hong Kong market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$2.13 per share.
Is New 90 Day High Low • Dec 22New 90-day high: HK$2.70The company is up 25% from its price of HK$2.16 on 24 September 2020. The Hong Kong market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$1.89 per share.
Valuation Update With 7 Day Price Move • Nov 09Market bids up stock over the past weekAfter last week's 17% share price gain to CN¥2.60, the stock is trading at a trailing P/E ratio of 10.4x, up from the previous P/E ratio of 8.9x. This compares to an average P/E of 7x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 3.7%.
Is New 90 Day High Low • Nov 06New 90-day high: HK$2.54The company is up 20% from its price of HK$2.11 on 07 August 2020. The Hong Kong market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is HK$1.53 per share.
Reported Earnings • Oct 02First half earnings releasedOver the last 12 months the company has reported total profits of CN¥872.4m, down 61% from the prior year. Total revenue was CN¥16.9b over the last 12 months, down 18% from the prior year.
